Insider Selling: Leonard Bell Sells 3,500 Shares of Alexion Pharmaceuticals Stock (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell unloaded 3,500 shares of the company’s stock on the open market in a transaction dated Monday, September 16th. The shares were sold at an average price of $115.00, for a total value of $402,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,026,293 shares in the company. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Goldman Sachs Group Inc. raised their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $122.00 to $139.00 in a research note to investors on Wednesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note to investors on Thursday, August 15th. They now have a $115.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note to investors on Tuesday, July 30th. They now have a $116.00 price target on the stock.
One investment analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $118.18.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.48% during mid-day trading on Wednesday, hitting $115.932. The stock had a trading volume of 837,161 shares. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $125.65. The stock’s 50-day moving average is $111.1 and its 200-day moving average is $100.8. The company has a market cap of $22.671 billion and a price-to-earnings ratio of 65.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $370.10 million for the quarter, compared to the consensus estimate of $364.80 million. During the same quarter last year, the company posted $0.47 earnings per share. Alexion Pharmaceuticals’s revenue was up 34.7% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.